Kisker, O <br/><br/>
Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model.  [electronic resource] 

 -  Cancer research  Oct 2001 
 - 7669-74 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0008-5472 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--administration & dosage<br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Carcinoma, Lewis Lung--blood supply<br/>Collagen--administration & dosage<br/>Drug Stability<br/>Endostatins<br/>Fibrosarcoma--blood supply<br/>Humans<br/>Infusion Pumps, Implantable<br/>Infusions, Parenteral<br/>Injections, Intraperitoneal<br/>Male<br/>Mice<br/>Mice, Inbred CBA<br/>Mice, SCID<br/>Neovascularization, Pathologic--drug therapy<br/>Osmotic Pressure<br/>Pancreatic Neoplasms--blood supply<br/>Peptide Fragments--administration & dosage<br/>Xenograft Model Antitumor Assays